108 related articles for article (PubMed ID: 2702012)
1. [Postmarketing surveillance of adverse reactions of drugs].
Polli EE; Cortellaro M
Ann Ital Med Int; 1989; 4(1):1-9. PubMed ID: 2702012
[No Abstract] [Full Text] [Related]
2. Multicenter study of hospital adverse drug reactions.
Conforti A; Leone R; Moretti U; Sartori M; Velo GP
Acta Physiol Hung; 1990; 75 Suppl():63-4. PubMed ID: 2196759
[No Abstract] [Full Text] [Related]
3. Active reporting scheme: an example to evaluate specific adverse drug reactions.
Pini LA; Sternieri E
Acta Physiol Hung; 1990; 75 Suppl():237-8. PubMed ID: 2371875
[No Abstract] [Full Text] [Related]
4. Measuring adverse drug reactions in a postmarketing surveillance system.
Fisher S; Bryant SG; Kluge RM
Psychopharmacol Bull; 1986; 22(1):272-7. PubMed ID: 3726073
[No Abstract] [Full Text] [Related]
5. Should new drugs be avoided?
Child Health Alert; 2002 Jun; 20():2. PubMed ID: 12096722
[No Abstract] [Full Text] [Related]
6. [Drug surveillance and adverse reactions to drugs. The literature and importance of historical data].
Mariani L; Minora T; Ventresca GP
Clin Ter; 1996 Dec; 147(12):653-72. PubMed ID: 9296925
[TBL] [Abstract][Full Text] [Related]
7. Controversies in adverse drug reaction reporting.
Juergens JP
Am J Hosp Pharm; 1990 Jan; 47(1):76-7. PubMed ID: 2301428
[No Abstract] [Full Text] [Related]
8. Monitoring adverse drug reactions in the postmarketing phase.
Hoigné R; Hottinger S
Pharm Acta Helv; 1988; 63(1):2-12. PubMed ID: 3283774
[No Abstract] [Full Text] [Related]
9. International Conference on Harmonisation; guidance on E2E Pharmacovigilance Planning; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2005 Apr; 70(62):16827-8. PubMed ID: 15803631
[TBL] [Abstract][Full Text] [Related]
10. [Minimal information that should be found in reports about suspected adverse reactions of drugs].
Laporte JR; Lience E
Med Clin (Barc); 1991 Jun; 97(2):56-7. PubMed ID: 1895784
[No Abstract] [Full Text] [Related]
11. Strategy for surveillance of adverse drug events.
Bright RA
Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
[No Abstract] [Full Text] [Related]
12. Adverse drug reactions: a review of relevant factors.
Ajayi FO; Sun H; Perry J
J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
[TBL] [Abstract][Full Text] [Related]
13. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
Joshi SR; Sapatnekar SM
J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
[No Abstract] [Full Text] [Related]
14. Toward improved adverse event/suspected adverse drug reaction reporting.
Gross R; Strom BL
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
[No Abstract] [Full Text] [Related]
15. Adverse drug reactions.
Turner P
Hum Toxicol; 1986 May; 5(3):161-2. PubMed ID: 3710492
[No Abstract] [Full Text] [Related]
16. Use of an algorithm to evaluate published reports of adverse drug reactions.
Case B; Oszko MA
Am J Hosp Pharm; 1991 Jan; 48(1):121-2. PubMed ID: 2000870
[No Abstract] [Full Text] [Related]
17. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions.
Fraunfelder FW; Fraunfelder FT
Am J Ophthalmol; 2007 Jan; 143(1):145-149. PubMed ID: 17188050
[TBL] [Abstract][Full Text] [Related]
18. European drug agency criticises Roche for failing to report adverse reactions and patient deaths.
Wise J
BMJ; 2012 Jun; 344():e4344. PubMed ID: 22736470
[No Abstract] [Full Text] [Related]
19. Notifying patients of adverse drug reactions.
Pane FJ; Ringer L; Ferguson L; Koshko N
Am J Hosp Pharm; 1991 Feb; 48(2):236-7. PubMed ID: 2003491
[No Abstract] [Full Text] [Related]
20. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
[No Abstract] [Full Text] [Related]
[Next] [New Search]
